...court that allegations against him should not detract from the potential of the biotech company's widely touted cancer drug, Erbitux, as a breakthrough treatment for cancer. "Whatever happens to me, I know that this breakthrough therapy will one day make...

...struggle to get its key cancer drug, Erbitux, approved for sale in the United States...has nothing to do with any concern about Erbitux, its testing or its regulatory process...helping to build the company and advancing Erbitux. Ms. Stewart was indicted in early June...

...ImClone's application for approval of Erbitux, which the company had touted as a promising...new study was released concluding that Erbitux was effective against cancer after all...not review ImClone's application for Erbitux, which company touts as promising cancer...

...approved the company's colon cancer drug, Erbitux. The last ImClone trade before the halt...customary" whenever a stock is halted. Erbitux was initially turned down by the FDA in...ImClone's distribution partner for Erbitux, fell 14 cents to $29.89. Prescription...

...new clinical trial for its cancer drug Erbitux. ImClone was up $6.54 at $22.06...even review ImClone's application for Erbitux in December, saying crucial data were...which has a deal with ImClone to market Erbitux, also rose, gaining $1.89 to $47...

...in December 2001 because he had received word the government was about to issue a negative report on the ImClone cancer drug Erbitux. Share credit report surprises for article Seen any errors on your credit report lately? Share your story with us by calling...

...down $4.03 at $51.97 Oppenheimer issued a research report that was pessimistic about the drug maker's sales of its Erbitux colon cancer drug. MedImmune Inc., down 73 cents at $23.76 The biotechnology firm said it would stop clinical trials...

...it would not review ImClone's application for approval of Erbitux, which the company had touted as a promising cancer drug...Just this week, a new study conducted in Europe, found Erbitux worked just as well as a cancer treatment as a disputed ImClone-sponsored...

...it would not review ImClone's application for approval of Erbitux, which the company had touted as a promising cancer drug...Just this week, a new study conducted in Europe, found Erbitux worked just as well as a cancer treatment as a disputed study...

...Waksal's life, but he continues to believe in ImClone and Erbitux as holding out real hope for millions of cancer patients...learning that his biotech company's effort to win approval for Erbitux had been rejected by the Food and Drug Administration. Aliza's...